Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Financing Activities: 2014-2025

Historic Cash from Financing Activities for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to $173.5 million.

  • ImmunityBio's Cash from Financing Activities rose 1013.59% to $173.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.3 million, marking a year-over-year increase of 20.53%. This contributed to the annual value of $281.6 million for FY2024, which is 49.56% down from last year.
  • ImmunityBio's Cash from Financing Activities amounted to $173.5 million in Q3 2025, which was up 0.41% from $172.8 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Cash from Financing Activities ranged from a high of $326.0 million in Q4 2021 and a low of -$982,000 during Q1 2025.
  • For the 3-year period, ImmunityBio's Cash from Financing Activities averaged around $107.8 million, with its median value being $106.9 million (2024).
  • Per our database at Business Quant, ImmunityBio's Cash from Financing Activities soared by 289,513.33% in 2023 and then plummeted by 109.60% in 2025.
  • Quarterly analysis of 5 years shows ImmunityBio's Cash from Financing Activities stood at $326.0 million in 2021, then plummeted by 66.27% to $109.9 million in 2022, then spiked by 82.41% to $200.5 million in 2023, then crashed by 46.68% to $106.9 million in 2024, then surged by 1,013.59% to $173.5 million in 2025.
  • Its Cash from Financing Activities was $173.5 million in Q3 2025, compared to $172.8 million in Q2 2025 and -$982,000 in Q1 2025.